CANAGLIFLOZIN

Search structure
Trade Names:
Synonyms:
Status: Approved (2011)
Entry Type: Small molecule
Molecule Category: Parent
ATC: A10BK02
UNII: 6S49DGR869

Structure
InChI Key XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
Smile Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1
InChI
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H27FO6S
Molecular Weight 462.54
AlogP 2.97
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 5.0
Polar Surface Area 90.15
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 31.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Sodium/glucose cotransporter 2 inhibitor DailyMed
Primary Target
Sodium/glucose cotransporter 2
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC05 family of sodium-dependent glucose transporters
2 2-7 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Diabetes Mellitus 4 D003920 ClinicalTrials
Heart Failure 3 D006333 ClinicalTrials
Diabetic Nephropathies 3 D003928 ClinicalTrials
Obesity 2 D009765 ClinicalTrials
Diabetes Mellitus, Type 1 2 D003922 ClinicalTrials
Renal Insufficiency 1 D051437 ClinicalTrials
Polycystic Ovary Syndrome 1 D011085 ClinicalTrials

Related Entries

MCS

Scaffolds

Mixture

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Infections and infestations
13.07
Metabolism and nutrition disorders
10.82
Skin and subcutaneous tissue disorders
8.38
Vascular disorders
8.32
Renal and urinary disorders
7.31
Endocrine disorders
7.17
Nervous system disorders
5.9
Surgical and medical procedures
5.51
Investigations
5.42
General disorders and administration site conditions
5.38
Musculoskeletal and connective tissue disorders
5.14
Injury, poisoning and procedural complications
4.05
Gastrointestinal disorders
3.8
Cardiac disorders
2.56

Cross References

Resources Reference
ChEBI 73274
ChEMBL CHEMBL2048484
DrugBank DB08907
DrugCentral 4758
FDA SRS 6S49DGR869
Guide to Pharmacology 4582
SureChEMBL SCHEMBL157162
ZINC ZINC000043207238
ChEMBL CHEMBL4594217
FDA SRS B2L6AES9XQ
SureChEMBL SCHEMBL322059
CONTENTS